IceCure Medical Announces That The Society Of Interventional Oncology Submitted A Petition To The National Comprehensive Cancer Network Breast Cancer Guidelines Panel To Include Percutaneous Cryoablation Without Surgical Excision As An Option For Breast Cancer

IceCure Medical Inks Distribution Agreement With Scovas Medical To Distribute IceCure's ProSense Cryoablation Systems In Netherlands

IceCure Medical Says JHM-IRB Of West Cancer Center & Research Institute In Germantown, Tennessee, Approves Post-Marketing Study For ProSense Cryoablation In Local Treatment Of Low-Risk Breast Cancer

Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TNCAESAREA, Israel,

IceCure Medical Highlights Peer‑Reviewed Publications Reinforcing Cryoablation’s Growing Clinical Role In Breast Cancer Treatment De‑Escalation, Including FDA Authorization Of ProSense, Updated ASBrS Guidelines, And Positive ICE3 5‑Yr Outcomes

New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second

Icecure Medical Q2 EPS $(1.37) Beats $(1.40) Estimate, Sales $889.000K Miss $1.450M Estimate

Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.40) by 2.14 percent. This is a 23.89 percent increase over losses of $(1.80) per share from